Sriram Venkataraman
CIK 1550642 · last filed 2023-01-30
Sriram Venkataraman is a corporate insider who has filed 14 SEC Form 4 insider transactions across 4 companies since 2016. Across all open-market trades the lifetime net is −$112.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $699.9M across reported positions. 3 SEC filings were submitted jointly with Lantheus Holdings, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OPTN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
65 EAST 55TH STREET, 18TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RVL Pharmaceuticals plc (RVLP) Delisted | Director | 23,730,864 | $0.03 | $669.2K | $12.40M | 2 | 2023-01-30 |
| RVL Pharmaceuticals plc (OSMT) Delisted | Director | 1,032,995 | $1.11 | $1.15M | $6.25M | 2 | 2020-11-23 |
| OptiNose, Inc. (OPTN) Delisted | Director | 675,758 | $9.60 | $6.49M | -$71.59M | 6 | 2020-06-12 |
| LNTH | Director | 7,004,395 | $99.92 | $699.88M | -$59.10M | 2 | 2017-03-21 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-30 | — | Notice (144) | −160,078 | -$16.0K | EDGAR |
| 2023-08-24 | — | Notice (144) | −140,767 | -$19.7K | EDGAR |
| 2023-01-30 | RVL Pharmaceuticals plc (RVLP) Delisted | Other (J) | −1,032,995 | $0 | EDGAR |
| 2022-08-09 | RVL Pharmaceuticals plc (RVLP) Delisted | Buy (P) | +8,000,000 | $12.40M | EDGAR |
| 2020-11-23 | RVL Pharmaceuticals plc (OSMT) Delisted | Other (J) | −4,936,926 | $0 | EDGAR |
| 2020-06-12 | OptiNose, Inc. (OPTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-15 | RVL Pharmaceuticals plc (OSMT) Delisted | Buy (P) | +1,250,000 | $6.25M | EDGAR |
| 2019-11-26 | OptiNose, Inc. (OPTN) Delisted | Sell (S) | −1,250,000 | -$11.46M | EDGAR |
| 2019-06-10 | OptiNose, Inc. (OPTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-13 | OptiNose, Inc. (OPTN) Delisted | Sell (S) | −2,875,000 | -$60.13M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.